Research Papers:
Tumorigenesis and peritoneal colonization from fallopian tube epithelium
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2264 views | HTML 2900 views | ?
Abstract
Sharon L. Eddie1, Suzanne M. Quartuccio1, Eoghainin Ó hAinmhire1, Georgette Moyle-Heyrman1, Dan D. Lantvit1, Jian-Jun Wei2, Barbara C. Vanderhyden3 and Joanna E. Burdette1
1 Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, IL, USA
2 Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
3 Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
Correspondence to:
Joanna E. Burdette, email:
Keywords: high-grade serous carcinoma, fallopian tube, PTEN, KRAS, p53, AKT
Received: February 21, 2015 Accepted: April 15, 2015 Published: May 04, 2015
Abstract
Ovarian cancer is the most lethal gynecological malignancy, primarily because its origin and initiation factors are unknown. A secretory murine oviductal epithelial (MOE) model was generated to address the hypothesis that the fallopian tube is an origin for high-grade serous cancer. MOE cells were stably altered to express mutation in p53, silence PTEN, activate AKT, and amplify KRAS alone and in combination, to define if this cell type gives rise to tumors and what genetic alterations are required to drive malignancy. Cell lines were characterized in vitro and allografted into mice. Silencing PTEN formed high-grade carcinoma with wide spread tumor explants including metastasis into the ovary. Addition of p53 mutation to PTEN silencing did not enhance this phenotype, whereas addition of KRAS mutation reduced survival. Interestingly, PTEN silencing and KRAS mutation originating from ovarian surface epithelium generated endometrioid carcinoma, suggesting that different cellular origins with identical genetic manipulations can give rise to distinct cancer histotypes. Defining the roles of specific signaling modifications in tumorigenesis from the fallopian tube/oviduct is essential for early detection and development of targeted therapeutics. Further, syngeneic MOE allografts provide an ideal model for pre-clinical testing in an in vivo environment with an intact immune system.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3985